Andrews Gavin P, Laverty Thomas P, Jones David S
School of Pharmacy, The Queen's University of Belfast, Belfast, Ireland.
Eur J Pharm Biopharm. 2009 Mar;71(3):505-18. doi: 10.1016/j.ejpb.2008.09.028. Epub 2008 Oct 18.
The process of mucoadhesion involving a polymeric drug delivery platform is a complex one that includes wetting, adsorption and interpenetration of polymer chains amongst various other processes. The success and degree of mucoadhesion bonding is influenced by various polymer-based properties such as the degree of cross-linking, chain length and the presence of various functional groupings. The attractiveness of mucosal-targeted controlled drug delivery of active pharmaceutical ingredients (APIs), has led formulation scientists to engineer numerous polymeric systems for such tasks. Formulation scientists have at their disposal a range of in vitro and in vivo mucoadhesion testing setups in order to select candidate adhesive drug delivery platforms. As such, mucoadhesive systems have found wide use throughout many mucosal covered organelles for API delivery for local or systemic effect. Evolution of such mucoadhesive formulations has transgressed from first-generation charged hydrophilic polymer networks to more specific second-generation systems based on lectin, thiol and various other adhesive functional groups.
涉及聚合物药物递送平台的粘膜粘附过程是一个复杂的过程，包括润湿、吸附以及聚合物链的相互渗透等各种其他过程。粘膜粘附结合的成功与否和程度受到各种基于聚合物的性质影响，例如交联度、链长以及各种官能团的存在。活性药物成分（API）的粘膜靶向控释给药的吸引力，促使制剂科学家设计出众多用于此类任务的聚合物系统。制剂科学家可以使用一系列体外和体内粘膜粘附测试装置，以选择候选的粘附性药物递送平台。因此，粘膜粘附系统已在许多覆盖粘膜的细胞器中广泛用于递送API，以产生局部或全身作用。此类粘膜粘附制剂已从第一代带电亲水性聚合物网络发展到基于凝集素、硫醇和各种其他粘附官能团的更具特异性的第二代系统。
